{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:14:16Z","timestamp":1759342456530,"version":"3.37.3"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T00:00:00Z","timestamp":1549324800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Preston Robert Tisch Brain Tumor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Overall survival (OS) in glioblastoma (GBM) is poor at an average of 14 to 18 months, and long-term survivors (LTS) of GBM are rare. LTS of GBM, defined as surviving &gt;5 years postdiagnosis, represent only 2% to 10% of all GBM patients. LTS of cancer are at high risk of developing second primary neoplasms. This study looks at occurrences of second primary neoplasms in LTS of GBM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Records from adult patients newly diagnosed with GBM between January 1, 1998 and February 8, 2010, were retrospectively reviewed to identify LTS, defined as patients who survived \u22655 years. We focused on the identification of a new diagnosis of cancer occurring at least 2 years after the initial GBM diagnosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We identified 155 LTS of GBM, with a median OS of 11.0 years (95% CI: 9.0 to 13.1 years) and a median follow-up of 9.6 years (95% CI: 8.7 to 10.7 years). In this cohort of patients, 13 (8.4%) LTS of GBM developed 17 secondary cancers. Eight could potentially be attributed to previous radiation and chemotherapy (skin cancer in radiation field [n = 4], leukemia [n = 2], low-grade glioma [n = 1], and sarcoma of the scalp [n = 1]). The other 9 cases included melanoma (n = 2), prostate cancer (n = 2), bladder cancer (n = 1), endometrioid adenocarcinoma (n = 1), basal cell carcinoma (n = 1), and renal cell carcinoma (n = 1).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Although second primary cancers are rare in GBM LTS, providers should continue close monitoring with appropriate oncologic care. Moreover, this highlights the need for survivorship care of patients with GBM.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/nop\/npz001","type":"journal-article","created":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T00:29:50Z","timestamp":1549326590000},"page":"386-391","source":"Crossref","is-referenced-by-count":5,"title":["Second primary cancers in long-term survivors of glioblastoma"],"prefix":"10.1093","volume":"6","author":[{"given":"Jung-Young","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer G","family":"Jackman","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Woodring","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances","family":"McSherry","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Duke University School of Medicine, Durham, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E","family":"Herndon","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Duke University School of Medicine, Durham, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annick","family":"Desjardins","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7588-032X","authenticated-orcid":false,"given":"Henry S","family":"Friedman","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5110-3868","authenticated-orcid":false,"given":"Katherine B","family":"Peters","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,2,4]]},"reference":[{"key":"2019092003412595600_CIT0001","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/978-1-60327-492-0_14","article-title":"Epidemiology of brain tumors","volume":"472","author":"Ohgaki","year":"2009","journal-title":"Methods Mol Biol"},{"issue":"5","key":"2019092003412595600_CIT0002","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"issue":"1","key":"2019092003412595600_CIT0003","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11060-011-0738-7","article-title":"Improved survival time trends for glioblastoma using the SEER 17 population-based registries","volume":"107","author":"Koshy","year":"2012","journal-title":"J Neurooncol"},{"issue":"6","key":"2019092003412595600_CIT0004","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s00701-013-1693-1","article-title":"The impact of improved treatment strategies on overall survival in glioblastoma patients","volume":"155","author":"Slotty","year":"2013","journal-title":"Acta Neurochir (Wien)"},{"issue":"10","key":"2019092003412595600_CIT0005","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"2019092003412595600_CIT0006","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s11060-008-9752-9","article-title":"Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival","volume":"92","author":"Patel","year":"2009","journal-title":"J Neurooncol"},{"issue":"4","key":"2019092003412595600_CIT0007","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s10143-015-0632-4","article-title":"Factors predictive of improved overall survival following stereotactic radiosurgery for recurrent glioblastoma","volume":"38","author":"Bir","year":"2015","journal-title":"Neurosurg Rev"},{"issue":"7","key":"2019092003412595600_CIT0008","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1200\/JCO.2009.24.8062","article-title":"Second malignant neoplasms in survivors of pediatric Hodgkin\u2019s lymphoma treated with low-dose radiation and chemotherapy","volume":"28","author":"O\u2019Brien","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019092003412595600_CIT0009","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.radonc.2013.01.002","article-title":"Second primary cancers after adjuvant radiotherapy in early breast cancer patients: a national population based study under the Danish Breast Cancer Cooperative Group (DBCG)","volume":"106","author":"Grantzau","year":"2013","journal-title":"Radiother Oncol"},{"issue":"5","key":"2019092003412595600_CIT0010","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/ijc.23601","article-title":"Increased risk of colon cancer after external radiation therapy for prostate cancer","volume":"123","author":"Rapiti","year":"2008","journal-title":"Int J Cancer"},{"issue":"3","key":"2019092003412595600_CIT0011","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/pbc.21153","article-title":"High incidence of meningioma in cranial irradiated survivors of childhood acute lymphoblastic leukemia","volume":"49","author":"Goshen","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"23","key":"2019092003412595600_CIT0012","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.2217\/fon.15.252","article-title":"Risk of secondary solid malignancies after allogeneic hematopoietic stem cell transplantation and preventive strategies","volume":"11","author":"Adhikari","year":"2015","journal-title":"Future Oncol"},{"issue":"1","key":"2019092003412595600_CIT0013","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1182\/blood-2010-07-294629","article-title":"Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning","volume":"117","author":"Majhail","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2019092003412595600_CIT0014","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1093\/neuonc\/not036","article-title":"Secondary hematological malignancies associated with temozolomide in patients with glioma","volume":"15","author":"Momota","year":"2013","journal-title":"Neuro Oncol"},{"issue":"4","key":"2019092003412595600_CIT0015","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/pbc.22090","article-title":"Non-Hodgkin lymphoma following temozolomide","volume":"53","author":"Sharma","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2019092003412595600_CIT0016","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11060-004-2028-0","article-title":"Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma","volume":"71","author":"Su","year":"2005","journal-title":"J Neurooncol"},{"issue":"2","key":"2019092003412595600_CIT0017","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s11060-008-9764-5","article-title":"Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia","volume":"93","author":"Chamberlain","year":"2009","journal-title":"J Neurooncol"},{"issue":"6","key":"2019092003412595600_CIT0018","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/00129804-200311000-00004","article-title":"Chemotherapy-induced secondary malignancies","volume":"26","author":"Vega-Stromberg","year":"2003","journal-title":"J Infus Nurs"},{"issue":"2","key":"2019092003412595600_CIT0019","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/1531-8249(199908)46:2<183::AID-ANA7>3.0.CO;2-7","article-title":"Which glioblastoma multiforme patient will become a long-term survivor? A population-based study","volume":"46","author":"Scott","year":"1999","journal-title":"Ann Neurol"},{"issue":"18","key":"2019092003412595600_CIT0020","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3238\/arztebl.2015.0320","article-title":"Secondary malignancies following treatment for Hodgkin\u2019s lymphoma in childhood and adolescence","volume":"112","author":"D\u00f6rffel","year":"2015","journal-title":"Dtsch Arztebl Int"},{"issue":"1","key":"2019092003412595600_CIT0021","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/nop\/npx034","article-title":"Survivorship care planning in neuro-oncology","volume":"5","author":"Leeper","year":"2018","journal-title":"Neurooncol Pract."},{"issue":"1","key":"2019092003412595600_CIT0022","first-page":"29","article-title":"Surveillance of the adult cancer survivor","volume":"91","author":"Wilbur","year":"2015","journal-title":"Am Fam Physician"},{"issue":"16","key":"2019092003412595600_CIT0023","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1093\/jnci\/djs298","article-title":"Radiation-related risk of basal cell carcinoma: a report from the childhood cancer survivor study","volume":"104","author":"Watt","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"2019092003412595600_CIT0024","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2353\/jmoldx.2008.070161","article-title":"Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology","volume":"10","author":"Allain","year":"2008","journal-title":"J Mol Diagn"},{"issue":"1","key":"2019092003412595600_CIT0025","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/neuonc\/nop011","article-title":"Inherited predisposition to glioma","volume":"12","author":"Kyritsis","year":"2010","journal-title":"Neuro Oncol"},{"issue":"21","key":"2019092003412595600_CIT0026","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1200\/JCO.2011.34.9852","article-title":"Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma","volume":"29","author":"Ruden","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Neuro-Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/nop\/article-pdf\/6\/5\/386\/30038861\/npz001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T03:41:37Z","timestamp":1568950897000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nop\/article\/6\/5\/386\/5306567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,4]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,2,4]]},"published-print":{"date-parts":[[2019,9,20]]}},"URL":"https:\/\/doi.org\/10.1093\/nop\/npz001","relation":{},"ISSN":["2054-2577","2054-2585"],"issn-type":[{"type":"print","value":"2054-2577"},{"type":"electronic","value":"2054-2585"}],"subject":[],"published-other":{"date-parts":[[2019,10]]},"published":{"date-parts":[[2019,2,4]]}}}